Epidermal growth factor receptor‐targeted treatment for advanced colorectal carcinoma
- 2 June 2005
- Vol. 103 (12), 2435-2446
- https://doi.org/10.1002/cncr.21123
Abstract
Substantial effort has focused on the development of novel targeted agents for treating patients with late‐stage colorectal carcinoma. These agents are designed specifically to inhibit biochemical processes associated with pathogenesis. Numerous molecules targeting the epidermal growth factor receptor have been investigated as therapeutic agents and appear to herald a shift in the treatment paradigm for colorectal carcinoma. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 62 references indexed in Scilit:
- Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?Journal of Clinical Pathology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Monoclonal antibodies as therapeutic agents for cancerThe Lancet Oncology, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor ReceptorJournal of Clinical Oncology, 2004
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002
- Progress in Colorectal Cancer ChemotherapyDrugs & Aging, 2000